SUBSCRIBE
SUBSCRIBE
News   Deals

Eli Lilly and Company “Very Much Opposed” to Merger: CEO

March 21, 2011 | 
1 min read
BEIJING (Reuters) - Drugmaker Eli Lilly (NYSE:LLY - News), which faces plunging sales due to competition and lapsing patents, will not merge with another peer to ride out any rough times ahead, chief executive John Lechleitr said on Saturday.
Mergers & acquisitions Asia
Eli Lilly and Company
MORE ON THIS TOPIC
Global communication network concept. Worldwide business. Human resources.
Drug Development
CRO Boom in APAC region, With China at the Forefront
November 19, 2025
 · 
5 min read
 · 
Jennifer Smith-Parker
FDA commissioner Marty Makary speaking on a Youtube video, wearing a dark suit and a blue tie
FDA
Makary Eyes ‘America-First’ User Fee Structure as Renewal Negotiations Approach
November 19, 2025
 · 
2 min read
 · 
Tristan Manalac
man pulling each of the opposite ends of a rope in black and white, on a blue background with some blank space on top
Mergers & acquisitions
UPDATE: Avadel Accepts Alkermes’ Revised $2.37B Counteroffer, Besting Lundbeck
November 19, 2025
 · 
3 min read
 · 
Tristan Manalac
Podcast
Billions More in M&A, Another Bidding War and More FDA Drama
November 19, 2025
 · 
1 min read
 · 
Heather McKenzie